Table 1 MERS-CoV monoclonal antibodies in development. Several groups have identified monoclonal antibodies that have at least shown potent neutralization against MERS-CoV, and in some cases, that have protected transgenic mice and NHPs from MERS-CoV disease after viral challenge.
Institution | Name | Source | Target | R&D |
|---|---|---|---|---|
Chinese Academy of Sciences, China | 4C2, 2E6 | RBD-immunized mouse | RBD | Mouse efficacy |
Dana-Farber Cancer Institute, USA; Abviro, USA | 3B11 (AV-3) | Human-antibody library | RBD | Mouse and NHP efficacy |
HUMABS Biomed, Switzerland | LCA60 | Human survivor | RBD | Mouse and NHP efficacy |
New York Blood Center, USA; Fudan University, China | Mersmab1 | S1 immunized mouse | RBD | In vitro |
Organic Vaccines, USA | m336, m337, m338 | Human-antibody library | RBD | Mouse, rabbit, and NHP efficacy |
National Institutes of Health, USA | D12, F11, G2, G4 | S/S1 immunized mouse | RBD, S1, S2 | NHP efficacy |
Regeneron, USA | REGN3048/REGN3051 | Humanized mouse | RBD | Mouse and NHP efficacy |
Tsinghua University, China | MERS-4, MERS-27 | Human-antibody library | RBD | In vitro |
S1, spike-domain-containing RBD; S2, spike-domain-containing fusion machinery. | ||||
